Avestar Capital LLC Sells 1,580 Shares of Eli Lilly and Company $LLY

Avestar Capital LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 17.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 7,501 shares of the company’s stock after selling 1,580 shares during the quarter. Avestar Capital LLC’s holdings in Eli Lilly and Company were worth $5,848,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $27,000. Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $31,000. Bare Financial Services Inc increased its position in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. Finally, Blume Capital Management Inc. raised its holdings in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,009.26 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The company has a market capitalization of $954.13 billion, a price-to-earnings ratio of 49.38, a PEG ratio of 1.13 and a beta of 0.37. The company has a 50-day simple moving average of $918.84 and a 200 day simple moving average of $809.30. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Berenberg Bank raised their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,087.32.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.